Gastrointestinal stromal tumor (GIST) · line 4 · Ripretinib monotherapy (advanced GIST, ≥4L after imatinib + sunitinib + regorafenib)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 4 |
|---|---|
| Track | aggressive |
| Linked regimen | REG-RIPRETINIB-GIST-4L |
| ID | IND-GIST-4L-RIPRETINIB |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-29 | pending_clinical_signoff |
| Diseases | DIS-GIST |
| Sources | SRC-INVICTUS SRC-NCCN-GIST-2025 |
Notes
STUB — pending Clinical Co-Lead sign-off. Aggressive-track 4L+ for advanced GIST after imatinib + sunitinib + regorafenib. Genotype gate: KIT-positive OR non-D842V PDGFRA — D842V routes to avapritinib branch. Ukraine access constraint dominant (not registered, not NSZU; out-of-pocket USD 32K/month). Algorithm wiring deferred — GIST 4L+ algorithm not yet authored in KB; out of chunk scope. SRC-INVICTUS already in KB; trial-anchor citation complete.
Used By
Algorithms
ALGO-GIST-2L- ALGO-GIST-2L